[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100485556":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":27,"locations":32,"responsibleParty":48,"collaborators":50,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Institute of Tropical Medicine, Belgium","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"VL patients",null,"VL infected individuals residing in\u002F with travel history to VL-endemic areas in Northern Ethiopia",[13],"Other: No intervention",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"No intervention",[9],[19,23],{"name":20,"affiliation":21,"role":22},"Saskia van Henten, MD","Institute of Tropical Medicine Antwerp, Antwerp, Belgium","STUDY_CHAIR",{"name":24,"affiliation":25,"role":26},"Eleni Ayele, MD","University of Gondar, Gondar, Ethiopia","PRINCIPAL_INVESTIGATOR",[28],{"name":20,"role":29,"phone":30,"phoneExt":10,"email":31},"CONTACT","+32(0)32476556","svanhenten@itg.be",[33],{"facility":34,"status":35,"city":36,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"University of Gondar","RECRUITING","Gonder","Ethiopia","ET",{"type":40,"coordinates":41},"Point",[42,43],37.46667,12.6,{"lat":43,"lon":42},[46],{"name":47,"role":29,"phone":10,"phoneExt":10,"email":10},"Eleni Ayele",{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[51],{"name":34,"class":6},"100485556","clinical-prognostic-score-to-predict-relapse-in-vl-100485556",false,"NCT05602610","Clinical Prognostic Score to Predict Relapse in VL","Comprehensive Clinical and Laboratory Assessment of Visceral Leishmaniasis to Develop Clinical Prognostic Tools to Predict Relapse: a Prospective Cohort Study in Ethiopia","CPS","Inclusion Criteria:\n\n* clinically or parasitologically confirmed VL\n\nExclusion Criteria:\n\n* Age under 12 years\n* VL patients already on treatment for 3 days or more\n* Severe critical condition or other circumstances that make the study medically inadvisable\n* Unlikely to adhere to follow up visits during the study period (e.g. patients who live or work very far away) AND not reachable by phone for follow-up information\n* Pregnant or lactating woman","ALL","12 Years",{"count":63,"type":64},741,"ESTIMATED","OBSERVATIONAL","This prospective cohort study has the aim to develop a prognostic tool to predict relapse in patients suffering from visceral leishmaniasis (VL) from VL endemic regions in Ethiopia.\n\nTherefore, comprehensive clinical and laboratory characterization of all confirmed VL patients before and during treatment will be performed in order to identify the factors that determine prognosis of the patients. This approach would result in more efficient patient care and would reduce the case fatality and morbidity, and improve follow-up and care for those at risk of VL relapse.",[68],"Visceral Leishmaniasis",[70,71,72,73,37],"leishmaniasis","visceral","neglected","relapse","2024-03-04",{"date":76,"type":77},"2024-03-05","ACTUAL",{"date":79,"type":77},"2023-02-03",{"date":81,"type":64},"2027-06-30",{"name":5,"class":6},1]